Author(s): Clarke G, Cryan JF, Dinan TG, Quigley EM, Clarke G, Cryan JF, Dinan TG, Quigley EM, Clarke G, Cryan JF, Dinan TG, Quigley EM, Clarke G, Cryan JF, Dinan TG, Quigley EM
Abstract Share this page
Abstract BACKGROUND: Irritable bowel syndrome (IBS) is a poorly understood, yet highly prevalent functional gastrointestinal disorder (FGID). The withdrawal, due to adverse events, of a number of pharmacological agents that were approved for the treatment of IBS has left a therapeutic vacuum for patients suffering from the disorder. AIM: To review, summarise and critically evaluate current knowledge of lactic acid bacteria (LAB) used to treat IBS. METHODS: We assessed a comprehensive range of relevant literature from Pubmed, Medline and online sources based on our definition of LAB which included both typical and atypical species, covering Lactobacilli, Bifidobacteria, Enterococci, Streptococci and Bacilli. RESULTS: Of the 42 trials evaluated examining the efficacy of LAB in IBS, 34 reported beneficial effects in at least one of the endpoints or symptoms examined, albeit with tremendous variation in both the magnitude of effect and the choice of outcome under consideration. However, numerous concerns have been expressed over deficits of trial design and execution relating to strain selection, optimum dosage, mode of action, safety and long-term tolerability in a disorder that can persist throughout the lifetime of affected individuals. CONCLUSIONS: Progress in the field will require an improved understanding of how the microbiota impacts on health and disease, adequately powered long-term multicentre trials and the embracing of bench to bedside approaches. Recent incremental advances suggest these areas are being addressed and that the future holds much promise for the use of lactic acid bacteria in the treatment of irritable bowel syndrome. © 2012 Blackwell Publishing Ltd.
This article was published in Aliment Pharmacol Ther
and referenced in Journal of Clinical Toxicology